Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliations: Trius Therapeutics, San Diego, California (Dr Prokocimer;firstname.lastname@example.org); and InClin Inc, San Mateo, California (Dr Das).
In Reply: Dr Spellberg raises the question of whether a cessation of lesion spread in ABSSSIs can be considered a cure of the disease. This issue was discussed by the Foundation for the National Institutes of Health working group on end points in ABSSSIs.1 The group's recommended end point is a 20% or greater decrease in lesion size at the 48- to 72-hour assessment rather than cessation of spread at this time point.
Prokocimer P, Das A. End Points in Trials of Treatments for Skin Infections—Reply. JAMA. 2013;309(20):2091–2092. doi:10.1001/jama.2013.4550
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: